XML 58 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814
Organization and Operations (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 9 Months Ended
Jun. 30, 2015
$ / shares
shares
Jun. 30, 2015
USD ($)
$ / shares
shares
Sep. 30, 2015
USD ($)
shares
Dec. 31, 2014
USD ($)
Minimum number of disease pathways within which multiple biological targets are modulated during treatment     1  
Number of bioactives used to engineer bi-functional product candidates     2  
Number of SMART linkers     1  
Initial public offering        
Common Stock issued upon conversion of Preferred Stock 9,029,549      
Number of shares after conversion of warrants     24,566  
Accumulated deficit | $     $ (98,404) $ (75,380)
Initial public offering        
Initial public offering        
Issuance of stock (in shares)   5,750,000    
Share price (in dollars per share) | $ / shares $ 12.00 $ 12.00    
Proceeds from initial public offering, net of issuance costs | $   $ 61,700    
Underwriting discounts, commissions and offering-related expenses payable | $   $ 7,300    
Common Stock issued upon conversion of Preferred Stock   9,029,549    
Initial public offering | Warrants for the purchase of Common Stock        
Initial public offering        
Number of shares after conversion of warrants 24,566 24,566    
Over-Allotment option for underwriters        
Initial public offering        
Issuance of stock (in shares)   750,000    
Preferred Stock | Initial public offering        
Initial public offering        
Preferred Stock warrants converted (in shares)   315,688